Dr. Raymond Y. Wang, MD
Pediatrics (Pediatrics Physician)
At a glance
- Medical school
- University of California, Geffen School of Medicine (2001)
- Years since graduation
- 25
- In the NPI registry since
- 2007
Licensed in California since 2002, according to the Medical Board of California. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2001Medical school: University of California, Geffen School of Medicine
- 2007Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Pediatrics Physician primary
CA license A80602 (first issued 2002; current)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Children's Hospital of Orange County Orange, CA
Medical groups
- Childrens Hospital of Orange County (73 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Vimizim (elosulfase alfa) | 14 |
| Galafold (migalastat hcl) | 13 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 2 companies reported 5 payments worth $8,675 in total to this clinician.
| BioMarin Pharmaceutical Inc. | $5,475 |
|---|---|
| Genzyme Corporation | $3,200 |
| Consulting Fee | $5,475 |
|---|---|
| Compensation for services other than consulting (speaking, faculty) | $3,200 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Genzyme Corporation Apr 29, 2025 | Compensation for services other than consulting (speaking, faculty) | $3,200 |
| BioMarin Pharmaceutical Inc. Dec 31, 2025 | Consulting Fee | $1,369 |
| BioMarin Pharmaceutical Inc. Dec 31, 2025 | Consulting Fee | $1,369 |
| BioMarin Pharmaceutical Inc. Dec 31, 2025 | Consulting Fee | $1,369 |
| BioMarin Pharmaceutical Inc. Dec 31, 2025 | Consulting Fee | $1,369 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 5 industry-funded studies in 2025, from 2 companies. The companies reported $26,162 in research payments for these studies, mostly to the institutions running them.
- Mucopolysaccharidosis VII Disease Monitoring Program
Ultragenyx Pharmaceutical Inc. · Recruiting · NCT03604835 - Fabry Disease Registry & Pregnancy Sub-registry
Sanofi US Services Inc. · Recruiting · NCT00196742 - Pompe Disease Registry Protocol
Sanofi US Services Inc. · Recruiting · NCT00231400 - International Collaborative Gaucher Group (ICGG) Gaucher Disease Registry & Pregnancy Sub-registry
Sanofi US Services Inc. · Recruiting · NCT00358943 - Mucopolysaccharidosis I (MPS I) Registry
Sanofi US Services Inc. · Completed · NCT00144794
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.